Feasibility and pharmacokinetic study of ch14.18 immunotherapy using teceleukin and CSF (mirimostim, filgrastim) for neuroblastoma
Latest Information Update: 08 Jun 2021
At a glance
- Drugs Dinutuximab (Primary) ; Filgrastim (Primary) ; Mirimostim (Primary) ; Teceleukin (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 08 Jun 2021 New trial record